Statera Biopharma Inc
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company develops therapies designed to directly elicit within patients a response of antigen-specific killer T-cells an… Read more
Statera Biopharma Inc (STAB) - Total Assets
Latest total assets as of September 2022: $12.75 Million USD
Based on the latest financial reports, Statera Biopharma Inc (STAB) holds total assets worth $12.75 Million USD as of September 2022.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Statera Biopharma Inc - Total Assets Trend (2011–2022)
This chart illustrates how Statera Biopharma Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Statera Biopharma Inc - Asset Composition Analysis
Current Asset Composition (December 2022)
Statera Biopharma Inc's total assets of $12.75 Million consist of 19.6% current assets and 80.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.7% |
| Accounts Receivable | $348.75K | 1.7% |
| Inventory | $1.81 Million | 8.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.58 Million | 7.5% |
| Goodwill | $9.27 Million | 43.8% |
Asset Composition Trend (2011–2022)
This chart illustrates how Statera Biopharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Statera Biopharma Inc's current assets represent 19.6% of total assets in 2022, a decrease from 96.5% in 2011.
- Cash Position: Cash and equivalents constituted 8.7% of total assets in 2022, down from 71.2% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 50.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is goodwill at 43.8% of total assets.
Statera Biopharma Inc Competitors by Total Assets
Key competitors of Statera Biopharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Statera Biopharma Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Statera Biopharma Inc generates 0.07x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Statera Biopharma Inc is currently not profitable relative to its asset base.
Statera Biopharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.05 | 1.31 | 4.33 |
| Quick Ratio | 0.05 | 0.95 | 4.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-21.01 Million | $ 3.15 Million | $ 7.37 Million |
Statera Biopharma Inc - Advanced Valuation Insights
This section examines the relationship between Statera Biopharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.16 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | $21.17 Million |
| Market Capitalization | $4.81K USD |
Valuation Analysis
Below Book Valuation: The market values Statera Biopharma Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Statera Biopharma Inc's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Statera Biopharma Inc (2011–2022)
The table below shows the annual total assets of Statera Biopharma Inc from 2011 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | $21.17 Million | 0.00% |
| 2021-12-31 | $21.17 Million | +1944.42% |
| 2020-12-31 | $1.04 Million | +62656.67% |
| 2019-12-31 | $1.65K | -99.96% |
| 2018-12-31 | $4.53 Million | -52.91% |
| 2017-12-31 | $9.63 Million | -39.65% |
| 2016-12-31 | $15.96 Million | -23.59% |
| 2015-12-31 | $20.88 Million | -99.41% |
| 2014-12-31 | $3.55 Billion | -75.86% |
| 2013-12-31 | $14.70 Billion | -54.09% |
| 2012-12-31 | $32.01 Billion | +99535.92% |
| 2011-12-31 | $32.13 Million | -- |